Spero therapeutics provides corporate update and 2024 outlook

In 2h 2024, expect to provide phase 2a topline proof-of-concept data from our wholly-owned lead program spr720 in ntm-pd patients

SPRO Ratings Summary

SPRO Quant Ranking